Opternative Sues Warby Parker Over Online Eye Exams

November 10, 2017: By Jon Swedien

legal issuesOpternative, the Chicago-based online vision test company, has filed a lawsuit against online eyewear retailer Warby Parker. The suit follows Warby Parker’s launch of a competing online vision test.

In the suit, filed Oct. 16, Opternative said Warby Parker breached nondisclosure agreements and misappropriated trade secrets when it launched its online eye exam in May 2017. Opternative launched its online eye exam in 2015.

In 2013, when Opternative was still developing its test, the company had discussions with Warby Parker about a potential partnership and possibly an acquisition by Warby Parker of Opternative.

During those discussions, Opternative said it required Warby Parker to sign nondisclosure agreements as it shared proprietary information. Opternative alleges Warby Parker violated those agreements in creating an online eye exam that is derivative of its own.

No partnership or acquisition was ever agreed to among the companies.

“Despite assurances to the contrary, Warby Parker had already developed an intent to develop its own online eye exam system, even as it negotiated for unfettered access to the inner workings of Opternative’s system,” the suit states.

Warby Parker has filed a motion to dismiss the lawsuit. In its motion to dismiss, Warby Parker said Opternative’s suit fails to show similarities between the two eye exams and the information Opternative shared was “limited, nontechnical information.”

“This action is an attempt by the plaintiff to recover through the courts where it has failed in the marketplace,” Warby Parker said in the motion.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Imprimis Will Comply with FDA Warning Letter

GenSight Receives UK Approval to Start Phase I/II Trial of Gene Therapy for Retinitis Pigmentosa

US FDA Outlines Compounding Policy, Defines Drugs that are ‘Essentially Copies’

Major US Hospitals Plan to Create Generic Drug Company, NYT Reports

Glaukos’ iDose Travoprost Implant Achieves Sustained IOP Reduction in 12-Month Interim Cohort

RXi Plans to Out-License Ophthalmic Segment or Find Development Partner

Bausch + Lomb Receives CE Marking for Stellaris Elite with Vitesse

Ohr’s Squalamine Combination Therapy Fails in Phase III Trial in Wet AMD

Iridex Sues Quantel Medical over Patent, Trademark Infringement

pSivida Submits NDA to US FDA for Durasert for Posterior Segment Uveitis

Alimera Sciences Refinances Debt with $40 Million Loan

LENSAR Acquires Mobile Laser Unit of Precision Eye Services

CES 2018 Features Dynafocals Smart Reading Glasses by PH Technical Labs

Novaliq Enrolls First Patient in Phase II Trial for Dry Eye Candidate, Establishes US Subsidiary

Allergan to Eliminate More than Thousand Jobs as Part of Restructuring

Spark Prices Luxturna at $850 Thousand, Looks to Offer Multiple Financing Plans

Oculis Raises $20.3 Million in Series B Round

Pixium Vision Gets Green Light for US Study of PRIMA Retinal Implant in Atrophic Dry AMD

Kala’s Dry Eye Candidate Meets Both Sign Endpoints, Misses One Symptom Endpoint in Phase III Studies

Pershing Square, Valeant Agree to Pay $290 Million in Settlement; Judge Will Decide Whether Deal is Fair

Coming soon

2018 Ophthalmic Surgical Instruments Report: A Global Market Analysis for 2017 to 2023